Solid Bio hit as FDA slaps clinical hold on DMD gene therapy

Roche joins others in dropping myostatin inhibitor for DMD

NS Pharma steals a march on Sarepta with DMD drug

FDA says no to Sarepta's golodirsen, blocking bid to expand ...

Sarepta DMD gene therapy could improve patients' motor funct...

Sarepta Therapeutics announced potentially game-changing results from its Duchenne muscular dystrophy gene therapy candidate, with a small phase 1 trial showing an improvement in patients’

Curing DMD: Travelling together to find a meaningful destina...

For many years, Duchenne muscular dystrophy (DMD) was something of a forgotten disease.